Praxis Precision Medicines Shares RADIANT Study Results

An announcement from Praxis Precision Medicines ( (PRAX) ) is now available.

On December 4, 2025, Praxis Precision Medicines announced the successful completion of its pre-New Drug Application meeting with the FDA for ulixacaltamide, aligning on the NDA content and planning to submit in early 2026. The company also reported positive results from the EMBOLD study for relutrigine, showing significant seizure reduction and functional improvements, with plans to discuss next steps with the FDA. Additionally, on December 6, 2025, Praxis shared results from the RADIANT study on vormatrigine, showing substantial seizure reduction in patients with focal onset seizures and generalized epilepsy, with ongoing studies set to continue into 2026.

The most recent analyst rating on (PRAX) stock is a Buy with a $507.00 price target. To see the full list of analyst forecasts on Praxis Precision Medicines stock, see the PRAX Stock Forecast page.

Spark’s Take on PRAX Stock

According to Spark, TipRanks’ AI Analyst, PRAX is a Neutral.

Praxis Precision Medicines’ overall stock score is driven by strong technical momentum and positive corporate events, which are offset by significant financial challenges and a poor valuation. The company’s recent advancements in drug development and regulatory progress provide optimism, but financial health remains a critical concern.

To see Spark’s full report on PRAX stock, click here.

More about Praxis Precision Medicines

Praxis Precision Medicines, Inc. operates in the pharmaceutical industry, focusing on developing treatments for neurological disorders. The company is engaged in creating innovative therapies for conditions such as developmental and epileptic encephalopathies and focal onset seizures.

Average Trading Volume: 997,445

Technical Sentiment Signal: Buy

Current Market Cap: $6.2B

For detailed information about PRAX stock, go to TipRanks’ Stock Analysis page.